Drug Approval | July 24, 2022
Dr. Reddy's announces the first-to-market, OTC launch of Allegra-D in the US market
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
